Marinus Pharmaceuticals (LTS:0JYL) Total Assets : $63.62 Mil (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Marinus Pharmaceuticals Total Assets?

Marinus Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2024 was $63.62 Mil.

During the past 12 months, Marinus Pharmaceuticals's average Total Assets Growth Rate was -12.30% per year. During the past 3 years, the average Total Assets Growth Rate was 25.30% per year. During the past 5 years, the average Total Assets Growth Rate was 48.10% per year. During the past 10 years, the average Total Assets Growth Rate was 37.60% per year.

During the past 12 years, Marinus Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 315.90%. The lowest was -10.10%. And the median was 38.40%.

Total Assets is connected with ROA %. Marinus Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2024 was -128.59%. Total Assets is also linked to Revenue through Asset Turnover. Marinus Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2024 was 0.11.

Marinus Pharmaceuticals Total Assets Historical Data

The historical data trend for Marinus Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinus Pharmaceuticals Total Assets Chart

Marinus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

98.84

150.46

136.84

259.52

170.91

Marinus Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Assets	Get a 7-Day Free Trial															200.81	170.91	137.35	87.08	63.62

Marinus Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Marinus Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	16.765	+	154.143
	=	170.91

Marinus Pharmaceuticals's Total Assets for the quarter that ended in Sep. 2024 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2024 )	+	Total Liabilities (Q: Sep. 2024 )
	=	-66.74	+	130.364
	=	63.62

Marinus Pharmaceuticals (LTS:0JYL) Total Assets Explanation

Total Assets is connected with ROA %.

Marinus Pharmaceuticals's annualized ROA % for the quarter that ended in Sep. 2024 is

ROA %	=	Net Income (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
	=	-96.9	/	( (87.083	+	63.624)	/ 2 )
	=	-96.9	/	75.3535
	=	-128.59 %

Note: The Net Income data used here is four times the quarterly (Sep. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Marinus Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2024 is

	Asset Turnover
=	Revenue (Q: Sep. 2024 )	/	( (Total Assets (Q: Jun. 2024 )	+	Total Assets (Q: Sep. 2024 ))	/ count )
=	8.541	/	( (87.083	+	63.624)	/ 2 )
=	8.541	/	75.3535
=	0.11

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Marinus Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Marinus Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Marinus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinus Pharmaceuticals Inc (LTS:0JYL) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Matsonford Road, Suite 500, 5 Radnor Corporate Center, Radnor, PA, USA, 19087

Website

https://www.marinuspharma.com

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Marinus Pharmaceuticals Headlines

No Headlines